ONCAlert | 2017 San Antonio Breast Cancer Symposium

Results for the Combination of Ublituximab and Ibrutinib in CLL

Jeff Sharman, MD
Published Online:1:13 PM, Fri July 7, 2017

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network,Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses findings of the phase III GENUINE study, which explored the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.